Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center have achieved a significant milestone as the first in the United States to use a revolutionary all-in-one high-density mapping and dual-energy ablation catheter. Approved recently by the U.S. Food and Drug Administration (FDA), the catheter is designed to treat persistent atrial fibrillation and atrial flutter, common heart arrhythmias affecting millions worldwide.
The innovative catheter combines two critical functions: delivering targeted energy to specific areas of the heart while simultaneously mapping the patient’s heart in real time.
The first procedure using the device was performed on November 7, 2024, by Dr. Andrea Natale, F.H.R.S., F.A.C.C., F.E.S.C., executive medical director of TCAI, and Dr. Amin Al-Ahmad, a clinical cardiac electrophysiologist. Dr. Natale, who also contributed to the clinical trials that led to FDA approval, highlighted the advantages of the catheter.
“This all-in-one, first-of-its-kind catheter allows physicians to map, ablate, and validate all with a single device, enhancing workflow flexibility and efficiency, ultimately enabling greater safety and efficacy,” Dr. Natale stated. “As global innovation for heart arrhythmias progresses, TCAI is proud to lead advancements for patients in Central Texas and beyond.”
The novel system offers unparalleled versatility, allowing physicians to tailor treatments during ablation procedures using pulsed field or radiofrequency energy delivery. The dual-energy capability is complemented by precise mapping, enhancing outcomes for patients with fast, irregular heart rhythms.
Pulsed field ablation uses short bursts of high-energy electrical pulses to destroy abnormal heart cells without excessive heat or cold, while radiofrequency ablation employs thermal energy for similar effects. Both approaches have shown significant promise in treating arrhythmias.
Earlier in 2024, TCAI conducted the nation’s first procedures using two newly approved pulsed field ablation catheters, further cementing its role as a leader in cardiac electrophysiology innovation.
TCAI boasts a cutting-edge facility with six advanced labs where world-renowned electrophysiologists perform a high volume of complex procedures, solidifying its reputation as a premier center for cardiac care.
